Now Recruiting

ENLIVEN

Pexidartinib (PLX3397): PLX108-10 Phase 3 TGCT — PVNS or GCT-TS

A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered Pexidartinib (PLX3397) in Subjects with Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

Study Design:



*TGCT = Tenosynovial Giant Cell Tumor

Primary Endpoint: Response Rate at Week 25 based on centrally read MRI scans and RECIST 1.1

Secondary Endpoints:

- Change in Tumor Volume Score and range of motion at Week 25
- Duration of response at Week 25
- Patient-reported Outcomes (PROs) at Week 25 including:
  - Brief Pain Inventory (BPI), Worst Pain Numeric Rating Scale (NRS) item, Patient-reported Outcome Measurement Information System (PROMIS) Physical Function Scale, Worst Stiffness NRS item

ClinicalTrials.gov Identifier: **NCT02371369**

Pexidartinib (PLX3397) is an investigational agent and is not approved by the FDA or any other worldwide regulatory agency as a treatment for any indication. Efficacy and safety have not been established. There is no guarantee that pexidartinib (PLX3397) will become commercially available.

For more information about this clinical trial, please visit: www.ENLIVENtrial.com

Daiichi-Sankyo

Passion for Innovation.
Compassion for Patients.™

Daiichi Sankyo, Inc · Two Hilton Court · Parsippany, NJ 07054

Printed in US 2016 DSON16100204 www.dsi.com